Clinical trials: Hospitalized Patients, open to volunteers
- Condition Hospitalized Patients
- Status Open to volunteers
- Funder type Industry (pharma, biotech, devices)
Acute on Chronic Systolic Congestive Heart Failure, Cardiorenal Syndrome
Feasibility of the SCD in Cardiorenal Syndrome Patients Awaiting LVAD
Cardiovascular disease is the leading cause of mortality in the US, accounting for 45% of all deaths. Chronic Heart Failure (CHF) is now understood to be a multi-system disease process involving not only the cardiovascular system…
- Trial name
- NEUTRALIZE-CRS (NCT03836482)
- Testing
- Selective Cytopheretic Device
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- SeaStar Medical
Acute Respiratory Distress Syndrome, ARDS
Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS)
To evaluate the safety and efficacy of intravenous (IV) administration of bone marrow mesenchymal stem cell derived extracellular vesicles (EVs), ExoFlo, versus placebo for the treatment of hospitalized patients with…
- Trial name
- NCT05354141
- Testing
- ExoFlo, Intravenous normal saline
- Where
- 32 sites in United States
- Volunteers
- 970 people
- Sponsor
- Direct Biologics, LLC
COVID-19
EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease
The purpose of this clinical trial is to learn about the safety, pharmacokinetics (pharmacokinetics helps us understand how the drug is changed and eliminated from your body after you take it), and efficacy (how well a study…
- Trial name
- NCT05261139
- Testing
- nirmatrelvir, ritonavir
- Where
- 73 sites in United States, Bulgaria and 5 more
- Volunteers
- 160 people
- Sponsor
- Pfizer
Acute Renal Failure (ARF), Acute Tubular Necrosis
Use of QRX3 for Acute Tubular Necrosis Type of Renal Failure in Hospitalized Patients ( QRX-3 in ARF)
Use of QRX-3 in hospitalized patients with pediatric and adult patients with acute tubular necrosis renal failure
- Trial name
- QRX3 in ARF (NCT07161843)
- Testing
- QRX-3
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Ebima Clifford Okundaye
Acute Respiratory Distress Syndrome (ARDS), ARDS
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab
This is a Phase 2 multicenter, randomized, double-blinded, placebo-controlled study that will evaluate the safety and efficacy of host-directed therapeutics in hospitalized adults diagnosed with Acute Respiratory Distress…
- Conditions
- Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress Syndrome
- Trial name
- NCT06701656
- Testing
- Cohort C: bevacizumab
- Where
- 41 sites in United States
- Volunteers
- 200 people
- Sponsor
- PPD Development, LP
Elderly Patients, Polypathology
Personalized Digital Remote Monitoring for Elderly Patients
Objective This clinical investigation aims to evaluate whether the EPOCA Remote Monitoring System (RMS) enhances care for elderly patients with multiple chronic conditions and reduces unplanned hospitalizations.
- Conditions
- Elderly Patients, Polypathology, Multiple Chronic Conditions
- Trial name
- EPOCARE (NCT06845917)
- Testing
- Remote Patient Monitoring system
- Volunteers
- 700 people
- Sponsor
- EPOCA U&I
Steroid Refractory GVHD
Safety, PK, PD, Dosing, and Efficacy of RLS-0071for the Treatment of Hospitalized Patients With Steroid-Refractory Acute Graft-versus-Host Disease
This study is a Open Label Prospective Dose-Ranging Escalation and Expansion Trial to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Dosing, and Efficacy of RLS-0071 for the secondary treatment of acute…
- Trial name
- AURORA (NCT06343792)
- Testing
- RLS-0071
- Where
- 11 sites in United States, Germany and 1 more
- Volunteers
- 66 people
- Sponsor
- ReAlta Life Sciences, Inc.
Systemic Lupus Erythematosus
Observational Study Investigating Demographic and Clinical Characteristics of SLE Patients in Egypt
Systemic lupus erythematosus (SLE) is an autoimmune condition characterized by a complicated, unclear etiology that involves various complex factors.
- Trial name
- ROSE (NCT07144514)
- Volunteers
- 276 people
- Sponsor
- AstraZeneca
Costs and Cost Analysis, Effectiveness
Hospital at Home Versus Inpatient Care: Costs and Effectiveness
Background and Objectives Hospital at Home (HaH) delivers hospital-level treatment to acutely ill patients in their own homes, including daily medical and nursing visits, infusions, physiotherapy, and diagnostics.
- Conditions
- Costs and Cost Analysis, Effectiveness, Patient Satisfaction
- Trial name
- NCT07274072
- Where
- Switzerland
- Volunteers
- 200 people
- Sponsor
- Hospital at Home AG
Acute Disease, Acute Hospitalization
Efficiency of the "Medidux" Smartphone App for Demission Management in Patients Medicated in Acute Admission Unit (AAU)
The goal of this clinical trial is to evaluate whether the use of the medidux™ smartphone app can optimize post-discharge management for patients admitted to Acute Admission Units (AAU) with non-urgent health complaints.
- Conditions
- Acute Disease, Acute Hospitalization, Coughing, Back Pain
- Trial name
- EffiDux (NCT06655337)
- Testing
- Smartphone Application for Post-Discharge Symptom Monitoring
- Where
- Switzerland
- Volunteers
- 417 people
- Sponsor
- Mobile Health AG
Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC)
A Study to Assess Sulbactam-durlobactam in Pediatric Patients With Acinetobacter Baumannii-calcoaceticus Complex Infection
The goal of this clinical trial is to investigate the use of Sulbactam-Durlobactam (SUL-DUR) in pediatric patients and is being conducted to collect pharmacokinetic (PK) and safety data to enable the identification of appropriate…
- Trial name
- NCT06801223
- Testing
- Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours), Sulbactam 20mg/kg-Durlobactam 20mg/kg (Every 8 hours), Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 8 hours)
- Where
- 4 sites in United States
- Volunteers
- 48 people
- Sponsor
- Innoviva Specialty Therapeutics
Acute Respiratory Distress Syndrome (ARDS), ARDS
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: Vilobelimab
This is a Phase 2 multicenter, randomized, double-blinded, placebo-controlled study that will evaluate the safety and efficacy of host-directed therapeutics in hospitalized adults diagnosed with Acute Respiratory Distress…
- Conditions
- Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress Syndrome
- Trial name
- NCT06701682
- Testing
- Cohort A: vilobelimab
- Where
- 41 sites in United States
- Volunteers
- 200 people
- Sponsor
- PPD Development, LP
Acute Respiratory Distress Syndrome (ARDS), ARDS
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)
This is a Phase 2 multicenter, randomized, double-blinded, placebo-controlled study that will evaluate the safety and efficacy of host-directed therapeutics in hospitalized adults diagnosed with Acute Respiratory Distress…
- Conditions
- Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress Syndrome
- Trial name
- NCT06703073
- Testing
- Cohort A: vilobelimab, Cohort B: paridiprubart, Cohort C: bevacizumab
- Where
- 41 sites in United States
- Volunteers
- 600 people
- Sponsor
- PPD Development, LP
Babesiosis
Oral Tafenoquine Plus Standard of Care Versus Placebo Plus Standard of Care for Babesiosis
This study is a double-blind, randomized, multisite, placebo-controlled trial comparing the safety and efficacy of TQ versus placebo in patients hospitalized for babesiosis with low risk for relapsing disease who will also be…
- Trial name
- NCT06207370
- Testing
- Tafenoquine
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- 60 Degrees Pharmaceuticals LLC
COPD (Chronic Obstructive Pulmonary Disease)
COPD Exacerbation Follow Up
The goal of this study is to evaluate the impact of implementing an AI-enabled clinical workflow tool (Viz COPD) on respiratory specialist follow up and clinical outcomes after an acute exacerbation.
- Trial name
- NCT07118306
- Where
- 5 sites in United States
- Volunteers
- 485 people
- Sponsor
- Viz.ai, Inc.
Acute Respiratory Distress Syndrome, Adult Respiratory Distress Syndrome
Anti-CD14 Treatment With IC14 in Hospitalized ARDS Patients
Hospitalized patients with ARDS will be randomized to intravenous treatment with a monoclonal antibody against CD14, called IC14, or placebo. They will be followed for 28 days.
- Conditions
- Acute Respiratory Distress Syndrome, Adult Respiratory Distress Syndrome, Acute Lung Injury, Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)
- Trial name
- NCT06513949
- Testing
- Atibuclimab
- Where
- 2 sites in United States
- Volunteers
- 56 people
- Sponsor
- Implicit Bioscience
Heart Failure, Heart Failure Hospitalization
Non-Invasive Hemodynamic Monitoring in Hospitalized Heart Failure
Heart failure hospitalization is associated with a high risk of early readmission and mortality. There is an unmet clinical need for low-burden, non-invasive methods to better understand congestion and hemodynamic status during…
- Conditions
- Heart Failure, Heart Failure Hospitalization, Heart Failure (HF)
- Trial name
- NCT07671742
- Where
- Sweden
- Volunteers
- 1,000 people
- Sponsor
- Acorai AB
Respiratory Tract Infections (RTI)
Retrospective Observational Multicenter Study on the Burden of Hospitalized Patients With Respiratory Tract Infection
This multicenter retrospective real-world data study will evaluate the burden of respiratory tract infection (RTI)-related hospitalizations in up to 10 Dutch hospitals between 2018 and 2026.
- Trial name
- NCT07691216
- Testing
- Respiratory tract infection hospitalisation
- Volunteers
- 70,000 people
- Sponsor
- LOGEX
Acute Respiratory Distress Syndrome (ARDS), ARDS
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Paridiprubart
This is a Phase 2 multicenter, randomized, double-blinded, placebo-controlled study that will evaluate the safety and efficacy of host-directed therapeutics in hospitalized adults diagnosed with Acute Respiratory Distress…
- Conditions
- Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress Syndrome
- Trial name
- NCT06701669
- Testing
- Cohort B: paridiprubart
- Where
- 41 sites in United States
- Volunteers
- 200 people
- Sponsor
- PPD Development, LP
Heart Failure
CCM OPEN HF Registry
The registry has been designed to evaluate the long-term safety and efficacy of CCM therapy in a real-world setting.
- Trial name
- CCM OPEN HF (NCT07112924)
- Where
- 30 sites in United States
- Volunteers
- 5,500 people
- Sponsor
- Impulse Dynamics